Latest information on COVID-19

Translational Molecular Imaging Laboratory (TMIL)

Dr. Juergen K. Willmann, founder and PI of the Translational Molecular Imaging Laboratory, was killed in an auto accident on January 8, 2018. We are devastated by this sudden and tragic loss. In his absence, we will carry on with the work that he started and will ensure that the legacy that he leaves is recognized as one of innovation and accomplishment in his field. Read More

~~~

This laboratory focuses on the development and clinical translation of novel molecular and functional imaging biomarkers with special focus on imaging abdominal and pelvic cancer including pancreatic, liver, renal, ovarian, and prostate cancer. We further advance clinically available radiological imaging modalities such as ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) as promising imaging tools for early detection and treatment monitoring of abdominal and pelvic cancer. Our mission is to integrate novel molecular and functional imaging strategies into clinical protocols for improved patient care in the near future.